"ADP-ribosyl Cyclase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
| Descriptor ID |
D051997
|
| MeSH Number(s) |
D08.811.277.450.430.400.060.500 D12.776.543.550.045
|
| Concept/Terms |
ADP-ribosyl Cyclase 1- ADP-ribosyl Cyclase 1
- 1, ADP-ribosyl Cyclase
- ADP ribosyl Cyclase 1
- Cyclase 1, ADP-ribosyl
- T10 Antigen
- Antigen, T10
- NIM-R5 Antigen
- NIM R5 Antigen
- CD38 Antigens
- ADPR Cyclase T10
- Cyclase T10, ADPR
- Acute Lymphoblastic Leukemia Cells Antigen CD38
- Lymphocyte Differentiation Antigen CD38
- Antigens, CD38
- CD38 Antigen
- ADPR Cyclase CD38
- CD38, ADPR Cyclase
- Cyclase CD38, ADPR
|
Below are MeSH descriptors whose meaning is more general than "ADP-ribosyl Cyclase 1".
Below are MeSH descriptors whose meaning is more specific than "ADP-ribosyl Cyclase 1".
This graph shows the total number of publications written about "ADP-ribosyl Cyclase 1" by people in this website by year, and whether "ADP-ribosyl Cyclase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 2 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "ADP-ribosyl Cyclase 1" by people in Profiles.
-
LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis. Circ Res. 2026 Jul 06; 139(2):e327427.
-
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia. N Engl J Med. 2026 Apr 09; 394(14):1388-1398.
-
IFN-? and CD38 in AML: a T-cell engagement made in heaven? Blood. 2024 04 18; 143(16):1556-1557.
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies. J Exp Clin Cancer Res. 2022 Jun 28; 41(1):210.
-
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021 04 29; 137(17):2337-2346.
-
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study. Cancer Sci. 2020 Dec; 111(12):4526-4539.
-
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 03 01; 131(9):995-999.
-
Implication of CD38 gene in autophagic degradation of collagen I in mouse coronary arterial myocytes. Front Biosci (Landmark Ed). 2017 01 01; 22(4):558-569.
-
Future therapeutic options for patients with Waldenstr?m macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215.
-
CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma. Cytometry B Clin Cytom. 2018 01; 94(1):129-135.